Business & Tech
SEC Looks to Revoke Securities Registration of Medfield Biotech Co.
Symbollon Pharmaceuticals has reportedly not filed with the SEC in more than two years.
The Securities and Exchange Commission is looking to revoke a Medfield biotech company's securities registration after it failed to file a quarterly report.
Symbollon Pharmaceuticals, which reportedly develops iodine-based agents, had not filed with the SEC since May 2011, according to the Boston Business Journal.
Moreover, the SEC plans to hold a public hearing on Symbollon's status as a publicly-traded company, according to BBJ. To read the SEC's notice of the hearing, click here.
Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
We’ve removed the ability to reply as we work to make improvements. Learn more here
